HD-IMMUNE-GMBH
24.1.2024 04:41:35 CET | Business Wire | Press release
HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman. HDI has acquired the patents and assets of the Huntington’s disease program from AFFiRiS AG. HDI has also closed a pre-seed financing round with an Austrian Business Angel and awarded an Austria Wirtschafts Service (AWS) pre-seed Grant. Furthermore, HDI announces the successful application with the Austrian Centre of Industrial Biotechnology (acib) Comet24 program allowing for HDI to collaborate with the Institute of Molecular Biotechnology (BOKU, University of Natural Resources and Life Sciences, Vienna) for HDI’s research programs.
Dr. Stefan Bartl, CEO of HDI, comments: “With the acquirement of the Huntington’s disease program that I was developing previously at AFFiRiS AG, HD Immune starts in a position where we have very impressive pre-clinical data demonstrating the efficacy of treating transgenic model of Huntington’s Disease with our lead monoclonal antibody C6-17, which has been recently published. We are in the process of humanizing this antibody for the treatment of patients aiming to slow down the progression of the disease, thereby increasing the quality of life for the patient. Currently there are no therapies that can directly treat the mutant Huntingtin protein available for patients.”
HD Immune’s new pre-clinical publication can be found on the company webpage for downloading: www.hdimmune.com
HD Immune and Huntington’s Disease
Huntington’s disease (HD) is a fatal neurodegenerative disease with clinical symptoms becoming manifest typically in the fourth decade of life and progress to a severe neurological and psychiatric deterioration of the patient. HD is a rare monogenetic disorder, where the mutation leads to a structurally changed mutant Huntingtin protein (mtHTT) which forms aggregates in the brain.
HD Immune is developing an antibody to target the mutated protein and remove it from the body. HDI has a lead antibody mAB C6-17 which lowers mtHTT in the blood, organs and CNS and, further, improved motor performance in transgenic mice expressing human mutant protein. Based on these results, HD Immune intends to further advance the development of a human therapeutic antibody to reduce the symptoms of the disease in the patient.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122135838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arc'teryx Appoints Avery Baker Chief Brand Officer27.1.2026 15:00:00 CET | Press release
Technical apparel and equipment brand appoints first-ever Chief Brand Officer and names Tobia Prevedello General Manager, EMEA Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today announced the appointment of Avery Baker as its first-ever Chief Brand Officer, a newly created executive role that marks a significant step in the company’s global evolution. Baker joins Arc’teryx as it continues to unlock brand potential, elevate global capabilities, and fuel long-term growth across North America, EMEA, APAC, and Greater China. Additionally, Tobia Prevedello was appointed General Manager, EMEA, bringing more than 20 years of international leadership experience across EMEA and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127462809/en/ Avery Baker, Chief Brand Officer As Chief Brand Officer, Baker will report to CEO Stuart Haselden and will lead global bra
Research From Lenovo Reveals AI Is Paying Off, Yet Most CIOs Aren’t Ready for What Comes Next27.1.2026 15:00:00 CET | Press release
CIOs anticipate up to 179% ROI on AI investments, with further efficiencies expected as Agentic AI scalesMore than half of organizations (60%) are in late-stage AI adoption – though only 27% have a comprehensive governance framework in placeOnly 21% of CIOs use Agentic AI today, with half (55%) exploring or piloting use casesHybrid AI emerges as preferred deployment model, used by almost two thirds (62%) Enterprises have moved decisively from AI pilots to scaled implementations, driven by proven benefits and expectations of significant financial returns, according to Lenovo CIO Playbook 2026 with research insights by IDC. Nearly half (46%) of AI proof-of-concepts have already progressed into production, with some organizations projecting returns of $2.79 for every dollar invested. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127255538/en/ Lenovo CIO Playbook 2026: The Race for Enterprise AI AI is now recognized as a cor
Ypê Deepens Partnership with Rimini Street to Accelerate Agentic AI and Maximize ERP Value27.1.2026 15:00:00 CET | Press release
Powered by Rimini Support™ for SAP and Rimini Agentic UX™, Ypê turns ERP stability into a launchpad for rapid, enterprise-wide Agentic AI innovation Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the expansion of its partnership with Ypê, the Brazilian consumer goods company whose products can be found in over 95% of Brazilian homes. This milestone marks a new phase in Ypê’s AI-first vision to build a frictionless company that delivers exceptional experiences for employees, customers and stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127970457/en/ Ypê Deepens Partnership with Rimini Street to Accelerate Agentic AI and Maximize ERP Value Building the Foundation for Innovation Starts with Support A Rimini Support™ client for its SAP S/4HANA system, Ypê is leveraging Rimini St
PQE Group Reports Solid Year-End Results, Strengthens Position through Innovation in Pharmaceuticals and Medical Devices27.1.2026 15:00:00 CET | Press release
Revenue gains, global expansion, industry recognition, and ESG leadership supported continued growth in 2025 2025 represented another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) that includes more than 2000 employees and 40+ offices worldwide. Recently named "Best Managed Company" by Deloitte Private for the sixth consecutive year, the Group achieved a rise in revenue, which reached € 105 millions in 2025, an increase of 7% compared to the €97,5M millions realized in 2024. Founded by CEO Gilda D'Incerti in 1998, PQE Group is a women-owned company that has received numerous industry certifications, including ISO/IEC 27001, which is the world's best-known standard for information security, and ISO 9001, which focuses on quality management systems. To enhance its ongoing global expansion efforts, in 2025 PQE further expanded in the APAC Region, continued to strengthen its presence in North America, and established new offices in
Indero CRO and the World Scleroderma Foundation Announce Strategic Collaboration to Advance Early Therapeutic Intervention in Systemic Sclerosis27.1.2026 15:00:00 CET | Press release
Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial designed to evaluate multiple investigational medicinal products (IMPs) for patients meeting VEDOSS criteria. This trial aims to intervene at the earliest stages of systemic sclerosis to improve long-term patient outcomes. This partnership brings together 2 leaders in their respective fields, Indero in clinical trial operations and WSF in Scleroderma research and advocacy, to create a powerful platform for innovation in rheumatology. The WSF SHIELD platform is led by Professor Francesco Del Galdo (Chair) and Professor Dinesh Khanna (Co-PI), with Professor Marco Matucci and Professor Yannick Allanore serving as WSF representatives on the steering committee. For pharmaceutical sponsors and biotech companies, this collaboration represents a unique opportunity to engage with a research initiati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom